KEFLIN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KEFLIN is a small-molecule injectable antibiotic approved in 1974 by Eli Lilly and Company. The drug is indicated for bacterial infections requiring parenteral therapy. It represents a legacy injectable antibiotic in the mature phase of its product lifecycle.
LOE Approaching
As a legacy injectable antibiotic approaching loss of exclusivity, brand team size is likely minimal with focus on institutional and managed care retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
KEFLIN presents limited career growth opportunities due to zero linked job postings and an approaching loss-of-exclusivity status. Roles available are primarily maintenance-focused, targeting hospital formulary management and institutional contracts rather than growth-oriented positions.
Field Sales Representative (Institutional)Account Manager (Hospital Systems)
Worked on KEFLIN at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.